Clinical Trials Browser

Phase 1/2 × Unknown × Brentuximab Vedotin × Clear all

NCT02098512 2022-10-27

Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients

Phase 1/2 Unknown

Hodgkin Disease